Structure and Function of an Fc Receptor for IgA and IgM
IgA 和 IgM Fc 受体的结构和功能
基本信息
- 批准号:7340730
- 负责人:
- 金额:$ 26.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-02-15 至 2010-01-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntibody FormationAntigen PresentationAntigen-Antibody ComplexAntigensAppearanceB-LymphocytesBacteriophagesBindingBinding SitesBiochemicalBlood CirculationCytoplasmic TailDataDendritic CellsEpithelial CellsFc ReceptorFigs - dietaryFollicular Dendritic CellsGene TargetingGenesGlycoproteinsGoalsHandHematopoieticHumanImmunoglobulin AImmunoglobulin MImmunoglobulinsIntestinesKidneyLeucineLigandsLinkLymphoid TissueMembraneMessenger RNAMolecularMucosal ImmunityMusNaturePaneth CellsPlayPolymeric Immunoglobulin ReceptorsProteinsRNA SplicingRoleSerineSideStructureStructure of germinal center of lymph nodeStructure-Activity RelationshipSystemTestingThreonineTissuesTonsilTransfectionTranslatingTubular formationTyrosineUrineVariantcell typecomparativeextracellularin vivointerestintestinal cryptmacrophagemicroorganism antigenmonocytemouse modelnovelprotein expressionreceptorreceptor internalizationresearch study
项目摘要
DESCRIPTION (provided by applicant): The overall goal of these studies is to define the structure/function relationship of a recently identified Fc receptor for IgA and IgM (Fcalpha/muR). The Ig-like domain at the amino terminus of the predicted Fcalpha/muR glycoprotein contains a sequence motif that is conserved in the polymeric Ig receptor of various species and is predicted to be the binding site for IgM and IgA. The Fcalpha/muR gene is expressed in both hematopoietic (B and monocyte/macrophages) and non-hematopoietic (kidney and intestine) tissues in both humans and mice. Preliminary studies of Fcalpha/muR expression in humans indicate an interesting cellular distribution: germinal centers with the appearance of follicular dendritic cells (FDC) in tonsil, proximal tubular epithelial cells in kidney and Paneth cells in small intestinal crypts. Unlike the mouse Fcalpha/muR, the human receptor is expressed only by the B cells that reside in secondary lymphoid tissues rather than those present in the circulation. A novel splice variant that is predicted to encode a soluble form of Fcalpha/muR has been identified in the kidney. These findings have led to the hypothesis that Fcalpha/muR plays multiple functional roles depending upon the cell types expressing it. Fcalpha/muR on FDC may trap IgM or IgA immune complexes and present the intact antigens to B cells in germinal centers. Fcalpha/muR expression by B cells may be closely linked with cellular activation. On the other hand, Fcalpha/muR in renal tubular epithelial cells and intestinal Paneth cells may play a protective role at portals of entry for antigens and microorganisms. These hypotheses will be tested through the following Specific Aims: 1) Determine the cellular distribution and molecular nature of Fcalpha/muR by using receptor-specific antibodies and Ig-ligands; 2) Define the newly identified Fcalpha/muR splice variant as a soluble form of receptor; 3) Determine the function of the membrane-bound Fcalpha/muR; and 4) Employ an Fcalpha/muR-deficient mouse model to explore the in vivo function of the Fca/alphaR.
描述(由申请方提供):这些研究的总体目标是确定最近鉴定的伊加和IgM Fc受体(Fcalpha/muR)的结构/功能关系。在预测的Fcalpha/muR糖蛋白的氨基末端的Ig样结构域包含在各种物种的多聚IG受体中保守的序列基序,并且预测为IgM和伊加的结合位点。Fcalpha/muR基因在人和小鼠的造血(B和单核细胞/巨噬细胞)和非造血(肾和肠)组织中表达。人类Fcalpha/muR表达的初步研究表明了一个有趣的细胞分布:扁桃体中出现滤泡树突状细胞(FDC),肾脏中出现近端肾小管上皮细胞,小肠隐窝中出现潘氏细胞的生发中心。与小鼠Fcalpha/muR不同,人受体仅由存在于次级淋巴组织中的B细胞而不是存在于循环中的那些表达。一种新的剪接变异体,预计编码可溶性形式的Fcalpha/muR已被确定在肾脏。这些发现导致了这样的假设:Fcalpha/muR根据表达它的细胞类型而发挥多种功能作用。FDC上的Fcalpha/muR可以捕获IgM或伊加免疫复合物,并将完整的抗原提呈给生发中心的B细胞。B细胞的Fcalpha/muR表达可能与细胞活化密切相关。另一方面,肾小管上皮细胞和肠潘氏细胞中的Fcalpha/muR可能在抗原和微生物进入的入口处起保护作用。这些假设将通过以下特定目的进行检验:1)通过使用受体特异性抗体和Ig-配体确定Fcalpha/muR的细胞分布和分子性质; 2)将新鉴定的Fcalpha/muR剪接变体定义为可溶形式的受体; 3)确定膜结合的Fcalpha/muR的功能;和4)使用Fca/alphaR缺陷小鼠模型来探索Fca/alphaR的体内功能。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The long elusive IgM Fc receptor, FcμR.
- DOI:10.1007/s10875-014-0022-7
- 发表时间:2014-07
- 期刊:
- 影响因子:9.1
- 作者:Kubagawa H;Oka S;Kubagawa Y;Torii I;Takayama E;Kang DW;Jones D;Nishida N;Miyawaki T;Bertoli LF;Sanders SK;Honjo K
- 通讯作者:Honjo K
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hiromi Kubagawa其他文献
Hiromi Kubagawa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hiromi Kubagawa', 18)}}的其他基金
Studies of Paired Immunoglobulin-Like Receptors
配对免疫球蛋白样受体的研究
- 批准号:
8082003 - 财政年份:2010
- 资助金额:
$ 26.97万 - 项目类别:
Studies of structure and function of an Fc receptor for IgM
IgM Fc 受体的结构和功能研究
- 批准号:
8091880 - 财政年份:2010
- 资助金额:
$ 26.97万 - 项目类别:
Structure and Function of an Fc Receptor for IgA and IgM
IgA 和 IgM Fc 受体的结构和功能
- 批准号:
7018461 - 财政年份:2004
- 资助金额:
$ 26.97万 - 项目类别:
Structure and Function of an Fc Receptor for IgA and IgM
IgA 和 IgM Fc 受体的结构和功能
- 批准号:
7179263 - 财政年份:2004
- 资助金额:
$ 26.97万 - 项目类别:
Structure and Function of an Fc Receptor for IgA and IgM
IgA 和 IgM Fc 受体的结构和功能
- 批准号:
6773549 - 财政年份:2004
- 资助金额:
$ 26.97万 - 项目类别:
Structure and Function of an Fc Receptor for IgA and IgM
IgA 和 IgM Fc 受体的结构和功能
- 批准号:
6850789 - 财政年份:2004
- 资助金额:
$ 26.97万 - 项目类别:
NOVEL PAIR OF IMMUNOGLOBULIN LIKE RECEPTORS IN MICE
小鼠体内的一对新型免疫球蛋白样受体
- 批准号:
6510761 - 财政年份:1998
- 资助金额:
$ 26.97万 - 项目类别:
Studies of Paired Immunoglobulin-Like Receptors
配对免疫球蛋白样受体的研究
- 批准号:
7074633 - 财政年份:1998
- 资助金额:
$ 26.97万 - 项目类别:
相似海外基金
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9981001 - 财政年份:2017
- 资助金额:
$ 26.97万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9751102 - 财政年份:2017
- 资助金额:
$ 26.97万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9397073 - 财政年份:2017
- 资助金额:
$ 26.97万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
10223410 - 财政年份:2017
- 资助金额:
$ 26.97万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
- 批准号:
7951676 - 财政年份:2008
- 资助金额:
$ 26.97万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
- 批准号:
7606036 - 财政年份:2006
- 资助金额:
$ 26.97万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7375053 - 财政年份:2005
- 资助金额:
$ 26.97万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7201220 - 财政年份:2004
- 资助金额:
$ 26.97万 - 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
- 批准号:
6980810 - 财政年份:2003
- 资助金额:
$ 26.97万 - 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
- 批准号:
6419444 - 财政年份:2000
- 资助金额:
$ 26.97万 - 项目类别: